APO Research
Talk to an analyst

APO RESEARCH · REPORT

Alpha-1-Antitrypsin Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Alpha-1-Antitrypsin Antibody Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchAlpha-1-Antitrypsin Antibody Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha-1-Antitrypsin Antibody Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Alpha-1-Antitrypsin Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha-1-Antitrypsin Antibody Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha-1-Antitrypsin Antibody Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Alpha-1-Antitrypsin Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Alpha-1-Antitrypsin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Alpha-1-Antitrypsin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Alpha-1-Antitrypsin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Alpha-1-Antitrypsin Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Alpha-1-Antitrypsin Antibody market include Abcam, Abnova, Boster Biological Technology, Creative Biolabs, Creative Diagnostics, G Biosciences, LSBio, NSJ Bioreagents and Santa Cruz Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Alpha-1-Antitrypsin Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Alpha-1-Antitrypsin Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alpha-1-Antitrypsin Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Alpha-1-Antitrypsin Antibody market.

Alpha-1-Antitrypsin Antibody Segment by Company

Abcam

Abnova

Boster Biological Technology

Creative Biolabs

Creative Diagnostics

G Biosciences

LSBio

NSJ Bioreagents

Santa Cruz Biotechnology

Signalway Antibody LLC

United States Biological

Merck

Thermo Fisher Scientific

Alpha-1-Antitrypsin Antibody Segment by Type

Polyclonal

Monoclonal

Alpha-1-Antitrypsin Antibody Segment by Application

Immunohistochemistry Frozen

Enzyme Linked Immunosorbent Assay

Western Blot

Others

Alpha-1-Antitrypsin Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Alpha-1-Antitrypsin Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Alpha-1-Antitrypsin Antibody key companies, revenue, market share, and recent developments.

3. To split the Alpha-1-Antitrypsin Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Alpha-1-Antitrypsin Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Alpha-1-Antitrypsin Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze Alpha-1-Antitrypsin Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha-1-Antitrypsin Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha-1-Antitrypsin Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha-1-Antitrypsin Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alpha-1-Antitrypsin Antibody industry.

Chapter 3: Detailed analysis of Alpha-1-Antitrypsin Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Alpha-1-Antitrypsin Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Alpha-1-Antitrypsin Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Alpha-1-Antitrypsin Antibody Industry Trends Table 2. Alpha-1-Antitrypsin Antibody Industry Drivers Table 3. Alpha-1-Antitrypsin Antibody Industry Opportunities and Challenges Table 4. Alpha-1-Antitrypsin Antibody Industry Restraints Table 5. Global Alpha-1-Antitrypsin Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Alpha-1-Antitrypsin Antibody Revenue Share by Company (2021-2026) Table 7. Global Alpha-1-Antitrypsin Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Alpha-1-Antitrypsin Antibody Key Company Manufacturing Base & Headquarters Table 9. Global Alpha-1-Antitrypsin Antibody Company, Product Type & Application Table 10. Global Alpha-1-Antitrypsin Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Alpha-1-Antitrypsin Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global Alpha-1-Antitrypsin Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Alpha-1-Antitrypsin Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Alpha-1-Antitrypsin Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Type (2021-2026) Table 20. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Frozen Table 22. Significant Companies of Enzyme Linked Immunosorbent Assay Table 23. Significant Companies of Western Blot Table 24. Significant Companies of Others Table 25. Global Alpha-1-Antitrypsin Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Alpha-1-Antitrypsin Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Alpha-1-Antitrypsin Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Application (2021-2026) Table 29. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Application (2027-2032) Table 30. Global Alpha-1-Antitrypsin Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Alpha-1-Antitrypsin Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Region (2021-2026) Table 33. Global Alpha-1-Antitrypsin Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Region (2027-2032) Table 35. Global Alpha-1-Antitrypsin Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Alpha-1-Antitrypsin Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Alpha-1-Antitrypsin Antibody Sales Value Market Share by Country (2021-2026) Table 38. Global Alpha-1-Antitrypsin Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Alpha-1-Antitrypsin Antibody Sales Value Market Share by Country (2027-2032) Table 40. Abcam Company Information Table 41. Abcam Business Overview Table 42. Abcam Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Abcam Alpha-1-Antitrypsin Antibody Product Portfolio Table 44. Abcam Recent Development Table 45. Abnova Company Information Table 46. Abnova Business Overview Table 47. Abnova Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Abnova Alpha-1-Antitrypsin Antibody Product Portfolio Table 49. Abnova Recent Development Table 50. Boster Biological Technology Company Information Table 51. Boster Biological Technology Business Overview Table 52. Boster Biological Technology Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Boster Biological Technology Alpha-1-Antitrypsin Antibody Product Portfolio Table 54. Boster Biological Technology Recent Development Table 55. Creative Biolabs Company Information Table 56. Creative Biolabs Business Overview Table 57. Creative Biolabs Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Creative Biolabs Alpha-1-Antitrypsin Antibody Product Portfolio Table 59. Creative Biolabs Recent Development Table 60. Creative Diagnostics Company Information Table 61. Creative Diagnostics Business Overview Table 62. Creative Diagnostics Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Creative Diagnostics Alpha-1-Antitrypsin Antibody Product Portfolio Table 64. Creative Diagnostics Recent Development Table 65. G Biosciences Company Information Table 66. G Biosciences Business Overview Table 67. G Biosciences Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. G Biosciences Alpha-1-Antitrypsin Antibody Product Portfolio Table 69. G Biosciences Recent Development Table 70. LSBio Company Information Table 71. LSBio Business Overview Table 72. LSBio Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. LSBio Alpha-1-Antitrypsin Antibody Product Portfolio Table 74. LSBio Recent Development Table 75. NSJ Bioreagents Company Information Table 76. NSJ Bioreagents Business Overview Table 77. NSJ Bioreagents Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. NSJ Bioreagents Alpha-1-Antitrypsin Antibody Product Portfolio Table 79. NSJ Bioreagents Recent Development Table 80. Santa Cruz Biotechnology Company Information Table 81. Santa Cruz Biotechnology Business Overview Table 82. Santa Cruz Biotechnology Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Santa Cruz Biotechnology Alpha-1-Antitrypsin Antibody Product Portfolio Table 84. Santa Cruz Biotechnology Recent Development Table 85. Signalway Antibody LLC Company Information Table 86. Signalway Antibody LLC Business Overview Table 87. Signalway Antibody LLC Alpha-1-Antitrypsin Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Signalway Antibody LLC Alpha-1-Antitrypsin Antibody Product Portfolio Table 89. Signalway Antibody LLC Recent Development Table 90. United States Biological Company Information Table 91. United States Biological Business Overview Table 92. United States Biological Alpha-1-Antitrypsin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. United States Biological Alpha-1-Antitrypsin Antibody Product Portfolio Table 94. United States Biological Recent Development Table 95. Merck Company Information Table 96. Merck Business Overview Table 97. Merck Alpha-1-Antitrypsin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Merck Alpha-1-Antitrypsin Antibody Product Portfolio Table 99. Merck Recent Development Table 100. Thermo Fisher Scientific Company Information Table 101. Thermo Fisher Scientific Business Overview Table 102. Thermo Fisher Scientific Alpha-1-Antitrypsin Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Thermo Fisher Scientific Alpha-1-Antitrypsin Antibody Product Portfolio Table 104. Thermo Fisher Scientific Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Alpha-1-Antitrypsin Antibody Product Image Figure 2. Global Alpha-1-Antitrypsin Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alpha-1-Antitrypsin Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global Alpha-1-Antitrypsin Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global Alpha-1-Antitrypsin Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Alpha-1-Antitrypsin Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Frozen Image Figure 13. Enzyme Linked Immunosorbent Assay Image Figure 14. Western Blot Image Figure 15. Others Image Figure 16. Global Alpha-1-Antitrypsin Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Alpha-1-Antitrypsin Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Application (2021-2032) Figure 19. Global Alpha-1-Antitrypsin Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Alpha-1-Antitrypsin Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Alpha-1-Antitrypsin Antibody Sales Value (2021-2032) & (US$ Million) Figure 22. North America Alpha-1-Antitrypsin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Alpha-1-Antitrypsin Antibody Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Alpha-1-Antitrypsin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Alpha-1-Antitrypsin Antibody Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Alpha-1-Antitrypsin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Alpha-1-Antitrypsin Antibody Sales Value (2021-2032) & (US$ Million) Figure 28. South America Alpha-1-Antitrypsin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Alpha-1-Antitrypsin Antibody Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Alpha-1-Antitrypsin Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Frozen
  • Enzyme Linked Immunosorbent Assay
  • Western Blot
  • Others
Companies covered
  • Abcam
  • Abnova
  • Boster Biological Technology
  • Creative Biolabs
  • Creative Diagnostics
  • G Biosciences
  • LSBio
  • NSJ Bioreagents
  • Santa Cruz Biotechnology
  • Signalway Antibody LLC
  • United States Biological
  • Merck
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Alpha-1-Antitrypsin Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Alpha-1-Antitrypsin Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Alpha-1-Antitrypsin Antibody Market Dynamics
  1. 2.1 Alpha-1-Antitrypsin Antibody Industry Trends
  2. 2.2 Alpha-1-Antitrypsin Antibody Industry Drivers
  3. 2.3 Alpha-1-Antitrypsin Antibody Industry Opportunities and Challenges
  4. 2.4 Alpha-1-Antitrypsin Antibody Industry Restraints
3 Alpha-1-Antitrypsin Antibody Market by Company
  1. 3.1 Global Alpha-1-Antitrypsin Antibody Company Revenue Ranking in 2025
  2. 3.2 Global Alpha-1-Antitrypsin Antibody Revenue by Company (2021-2026)
  3. 3.3 Global Alpha-1-Antitrypsin Antibody Company Ranking (2024-2026)
  4. 3.4 Global Alpha-1-Antitrypsin Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global Alpha-1-Antitrypsin Antibody Company Product Type and Application
  6. 3.6 Global Alpha-1-Antitrypsin Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Alpha-1-Antitrypsin Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Alpha-1-Antitrypsin Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Alpha-1-Antitrypsin Antibody Market by Type
  1. 4.1 Alpha-1-Antitrypsin Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global Alpha-1-Antitrypsin Antibody Sales Value by Type
  5. 4.2.1 Global Alpha-1-Antitrypsin Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Alpha-1-Antitrypsin Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global Alpha-1-Antitrypsin Antibody Sales Value Share by Type (2021-2032)
5 Alpha-1-Antitrypsin Antibody Market by Application
  1. 5.1 Alpha-1-Antitrypsin Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry Frozen
  3. 5.1.2 Enzyme Linked Immunosorbent Assay
  4. 5.1.3 Western Blot
  5. 5.1.4 Others
  6. 5.2 Global Alpha-1-Antitrypsin Antibody Sales Value by Application
  7. 5.2.1 Global Alpha-1-Antitrypsin Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Alpha-1-Antitrypsin Antibody Sales Value by Application (2021-2032)
  9. 5.2.3 Global Alpha-1-Antitrypsin Antibody Sales Value Share by Application (2021-2032)
6 Alpha-1-Antitrypsin Antibody Regional Value Analysis
  1. 6.1 Global Alpha-1-Antitrypsin Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Alpha-1-Antitrypsin Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global Alpha-1-Antitrypsin Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global Alpha-1-Antitrypsin Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Alpha-1-Antitrypsin Antibody Sales Value (2021-2032)
  7. 6.3.2 North America Alpha-1-Antitrypsin Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Alpha-1-Antitrypsin Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe Alpha-1-Antitrypsin Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Alpha-1-Antitrypsin Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Alpha-1-Antitrypsin Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Alpha-1-Antitrypsin Antibody Sales Value (2021-2032)
  16. 6.6.2 South America Alpha-1-Antitrypsin Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Alpha-1-Antitrypsin Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Alpha-1-Antitrypsin Antibody Sales Value Share by Country, 2025 VS 2032
7 Alpha-1-Antitrypsin Antibody Country-level Value Analysis
  1. 7.1 Global Alpha-1-Antitrypsin Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Alpha-1-Antitrypsin Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global Alpha-1-Antitrypsin Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global Alpha-1-Antitrypsin Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Alpha-1-Antitrypsin Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Alpha-1-Antitrypsin Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Alpha-1-Antitrypsin Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abcam
  2. 8.1.1 Abcam Company Information
  3. 8.1.2 Abcam Business Overview
  4. 8.1.3 Abcam Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abcam Alpha-1-Antitrypsin Antibody Product Portfolio
  6. 8.1.5 Abcam Recent Developments
  7. 8.2 Abnova
  8. 8.2.1 Abnova Company Information
  9. 8.2.2 Abnova Business Overview
  10. 8.2.3 Abnova Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abnova Alpha-1-Antitrypsin Antibody Product Portfolio
  12. 8.2.5 Abnova Recent Developments
  13. 8.3 Boster Biological Technology
  14. 8.3.1 Boster Biological Technology Company Information
  15. 8.3.2 Boster Biological Technology Business Overview
  16. 8.3.3 Boster Biological Technology Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boster Biological Technology Alpha-1-Antitrypsin Antibody Product Portfolio
  18. 8.3.5 Boster Biological Technology Recent Developments
  19. 8.4 Creative Biolabs
  20. 8.4.1 Creative Biolabs Company Information
  21. 8.4.2 Creative Biolabs Business Overview
  22. 8.4.3 Creative Biolabs Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Creative Biolabs Alpha-1-Antitrypsin Antibody Product Portfolio
  24. 8.4.5 Creative Biolabs Recent Developments
  25. 8.5 Creative Diagnostics
  26. 8.5.1 Creative Diagnostics Company Information
  27. 8.5.2 Creative Diagnostics Business Overview
  28. 8.5.3 Creative Diagnostics Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Creative Diagnostics Alpha-1-Antitrypsin Antibody Product Portfolio
  30. 8.5.5 Creative Diagnostics Recent Developments
  31. 8.6 G Biosciences
  32. 8.6.1 G Biosciences Company Information
  33. 8.6.2 G Biosciences Business Overview
  34. 8.6.3 G Biosciences Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 G Biosciences Alpha-1-Antitrypsin Antibody Product Portfolio
  36. 8.6.5 G Biosciences Recent Developments
  37. 8.7 LSBio
  38. 8.7.1 LSBio Company Information
  39. 8.7.2 LSBio Business Overview
  40. 8.7.3 LSBio Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 LSBio Alpha-1-Antitrypsin Antibody Product Portfolio
  42. 8.7.5 LSBio Recent Developments
  43. 8.8 NSJ Bioreagents
  44. 8.8.1 NSJ Bioreagents Company Information
  45. 8.8.2 NSJ Bioreagents Business Overview
  46. 8.8.3 NSJ Bioreagents Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NSJ Bioreagents Alpha-1-Antitrypsin Antibody Product Portfolio
  48. 8.8.5 NSJ Bioreagents Recent Developments
  49. 8.9 Santa Cruz Biotechnology
  50. 8.9.1 Santa Cruz Biotechnology Company Information
  51. 8.9.2 Santa Cruz Biotechnology Business Overview
  52. 8.9.3 Santa Cruz Biotechnology Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Santa Cruz Biotechnology Alpha-1-Antitrypsin Antibody Product Portfolio
  54. 8.9.5 Santa Cruz Biotechnology Recent Developments
  55. 8.10 Signalway Antibody LLC
  56. 8.10.1 Signalway Antibody LLC Company Information
  57. 8.10.2 Signalway Antibody LLC Business Overview
  58. 8.10.3 Signalway Antibody LLC Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Signalway Antibody LLC Alpha-1-Antitrypsin Antibody Product Portfolio
  60. 8.10.5 Signalway Antibody LLC Recent Developments
  61. 8.11 United States Biological
  62. 8.11.1 United States Biological Company Information
  63. 8.11.2 United States Biological Business Overview
  64. 8.11.3 United States Biological Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 United States Biological Alpha-1-Antitrypsin Antibody Product Portfolio
  66. 8.11.5 United States Biological Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck Alpha-1-Antitrypsin Antibody Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Thermo Fisher Scientific
  74. 8.13.1 Thermo Fisher Scientific Company Information
  75. 8.13.2 Thermo Fisher Scientific Business Overview
  76. 8.13.3 Thermo Fisher Scientific Alpha-1-Antitrypsin Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Thermo Fisher Scientific Alpha-1-Antitrypsin Antibody Product Portfolio
  78. 8.13.5 Thermo Fisher Scientific Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst